Taldefgrobep Alfa in Adults With Overweight and Obesity

Running, not enrolling · Phase 2 · Has a placebo group

Conditions studied: Obesity, Overweight

In brief

This is a multicenter, randomized, double-blind, placebo-controlled, multiple dose study to evaluate the efficacy, safety, and tolerability of taldefgrobep alfa in adults with overweight and obesity, with an open-label extension.

Key facts

Study ID

NCT07281495

Run by

Biohaven Therapeutics Ltd.

People needed

150

Starts

2025-11-24

Expected to finish

2026-09-01

Last updated by the study team

2026-03-20

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Site-001 — Chula Vista, California, United States
• Site-014 — Montclair, California, United States
• Site-011 — Sacramento, California, United States
• Site-018 — Tustin, California, United States
• Site-020 — Orlando, Florida, United States
• Site-008 — Palm Springs, Florida, United States
• Site-015 — St. Petersburg, Florida, United States
• Site-007 — Chicago, Illinois, United States
• Site-016 — Indianapolis, Indiana, United States
• Site-010 — Baton Rouge, Louisiana, United States
• Site-009 — Metairie, Louisiana, United States
• Site-006 — City of Saint Peters, Missouri, United States
• Site-003 — Springfield, Missouri, United States
• Site-019 — Monroe, North Carolina, United States
• Site-002 — Fargo, North Dakota, United States
• Site-017 — North Charleston, South Carolina, United States
• Site-005 — Austin, Texas, United States
• Site-012 — McKinney, Texas, United States
• Site-013 — San Antonio, Texas, United States
• Site-004 — Arlington, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.